GlassScriptPhysician profile
Tsung-Hao Wu
NPI 1023469046
$3,170.34
in general payments reported to CMS, 2019-2025
26 companies · $521 in 2025
The $521 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $294 · 2021: $495 · 2022: $520 · 2023: $232 · 2024: $633 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $456.72 | 2019-2022 | |
| Alcon Vision LLC | $366.65 | 2019-2025 | Dailies Total1, Total30, Precision7 |
| Tarsus Pharmaceuticals, INC. | $254.86 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $218.66 | 2021-2025 | Idose, Photrexa Viscous and Photrexa |
| Bausch & Lomb Americas INC. | $210.33 | 2024-2025 | Miebo, Xiidra, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $201.10 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $178.80 | 2019-2025 | |
| Sight Sciences, INC. | $148.93 | 2019-2021 | |
| Coopervision INC. | $145.25 | 2020-2025 | Onefit Contact Lens, Misight Contact Lens, Paragon Crt |
| Oyster Point Pharma, INC. | $127.34 | 2022-2023 | Tyrvaya |
| New World Medical,INC. | $113.67 | 2023 | |
| Horizon Therapeutics Plc | $111.84 | 2022 | |
| Allergan, INC. | $107.36 | 2020-2021 | |
| Lkc Technologies, INC. | $90.88 | 2024 | |
| Dompe US, INC. | $83.65 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $61.80 | 2021-2025 | Contact Lens |
| Visionix USA, INC | $55.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $40.52 | 2020 | |
| Astellas Pharma US INC | $37.05 | 2024 | Izervay |
| Synergeyes, INC. | $36.00 | 2020 | |
| Abbvie INC. | $35.34 | 2022 | |
| Kala Pharmaceuticals, INC. | $20.09 | 2021 | |
| Shire North American Group INC | $19.95 | 2019 | |
| Optos, INC. | $17.07 | 2020 | |
| Visioneering Technologies, INC. | $16.52 | 2019 | |
| Biotissue Holdings INC. | $14.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tsung-Hao Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.